A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer
Hans P.M.W. Wildiers, MD, PhD (U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium)
Etienne Brain, MD (Institut Curie, Paris)